

# 2023 ESMO GYNAECOLOGICAL CANCERS

Annual Congress

BARCELONA SPAIN  
23-24 FEBRUARY 2023



## PRELIMINARY PROGRAMME

Thursday, 23 February 2023

### Educational session

Thursday, 23 February 2023, 08:30-09:50 CET

80'	<b>Treatment of ovarian cancer in 2023</b>
5'	Introduction
15'	Do we still need radical surgery in the PARP inhibitor era?
15'	How to select the best first line maintenance treatment? Is molecular profiling the only criteria to choose?
15'	New treatment in the current ovarian cancer beyond ADCs
15'	PARP inhibitors: Mechanism of resistance and how to overcome
15'	Q&A

### Special Symposium

Thursday, 23 February 2023, 10:15-11:35 CET

80'	<b>How to interpret overall survival data with PARP inhibitors</b>
15'	Why are we having this Symposium? Recent regulatory actions by FDA/EMA regarding late-stage approval for PARPi in recurrent ovarian cancer
15'	Is there clinical evidence to support the link between PARPi use and a negative impact on OS?
15'	Is there a biological rationale to support decremental impact on overall survival?
15'	What is the impact of overall survival results of PARP inhibitor trials?
20'	Q&A

### Abstract session (Programme to be announced)

Thursday, 23 February 2023, 11:45-12:45 CET

### Poster Display session

Thursday, 23 February 2023, 13:00-13:45 CET

### Industry satellite symposium 1 (TBC)

Thursday, 23 February 2023, 13:45-14:45 CET

## Thursday, 23 February 2023 (cont.)

### Controversy session

Thursday, 23 February 2023, 15:00-16:00 CET

60'	<b>How hot is HIPEC treatment in ovarian cancer?</b>
10'	Introduction and first vote
20'	The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO)
20'	HIPEC is not "IT" (CON)
10'	Second vote and conclusions

### Educational session

Thursday, 23 February 2023, 16:30-17:50 CET

80'	<b>ADCs in gynaecological cancers</b>
5'	Introduction
15'	Understanding the basics: Structure, key properties, mechanism of action, optimal diagnostic test to determine the target
15'	The evolving ADC treatment landscape in ovarian cancer
15'	Role of ADCs in cervical cancer treatment in the era of immunotherapy
15'	The new challenge: ADC class effects, on/off-target adverse reactions and their interdisciplinary management
15'	Q&A

### Industry satellite symposium 2 (TBC)

Thursday, 23 February 2023, 18:00-19:00 CET

*Friday, 24 February 2023: next page*

## Friday, 24 February 2023

### Educational session

Friday, 24 February 2023, 08:30-09:50 CET

<b>80'</b>	<b><i>Is cervical cancer still an orphan disease?</i></b>
5'	Introduction
15'	Molecular profiling and pathology of cervical cancer patients: Are HPV negative tumors a different entity?
15'	Can we improve the prognosis of locally advanced cervical cancer?
15'	Immunotherapy in cervical cancer: A paradigm shift
15'	Innovative techniques in radiation oncology to increase cure and reduce toxicity
15'	Q&A

### Educational session

Friday, 24 February 2023, 10:15-11:35 CET

<b>80'</b>	<b><i>Endometrial cancer</i></b>
5'	Introduction
15'	Revisiting the adjuvant therapy in endometrial cancer: ESMO Guidelines
15'	Is immunotherapy changing the face of recurrent/metastatic endometrial cancer?
15'	Are all dMMR/MSI-H endometrial cancer the same disease?
15'	Beyond immunotherapy: What is the role of HER2, p53 and other molecular targets in the recurrent/metastatic endometrial cancer treatment landscape?
15'	Q&A

### Keynote lecture

Friday, 24 February 2023, 11:45-12:15 CET

<b>30'</b>	<b>Keynote address</b>
5'	Introduction to the Keynote lecture
25'	The evolving role of surgery in gynaecological cancers

### Industry satellite symposium 3 (TBC)

Friday, 24 February 2023, 13:15-14:15 CET

### Multidisciplinary Tumour Board

Friday, 24 February 2023, 14:30-15:50 CET

<b>80'</b>	<b><i>Rare cancers</i></b>
5'	Introduction
20'	State-of-the-art management in carcinosarcoma: From the biology to treatment
20'	Is immune therapy definitely required for all clear cell carcinoma?
20'	Which drugs could be relevant for LGSC: The present and future
15'	Q&A

### Special session

Friday, 24 February 2023, 16:15-17:35 CET

<b>80'</b>	<b><i>Clinical trial highlights</i></b>
	<i>Programme to be announced</i>